The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
The investigation is in relation to drug pricing in the pharmaceutical industry.
Demographic trends that boosted big gains in prior years haven't gone away.
Impax Laboratories CEO G. Frederick Wilkinson steps down amid a Department of Justice generic price-fixing investigation. J. Kevin Buchi, who joined the board last month, was tapped as interim CEO.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.